Eisai Korea has launched Equfina (safinamide) in South Korea as an add-on therapy to levodopa for people with Parkinson’s disease who are experiencing “off” episodes. Equfina was approved in South Korea last year and this represents the medication’s first launch in Asia outside of Japan. Marketed as Xadago in the U.S., Europe, and Australia, and as Onstryv in Canada, safinamide boosts the brain’s amount of available dopamine, a signaling molecule needed to coordinate movement that is…

You must be logged in to read/download the full post.